Plain-English translation of NCT05407519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether tislelizumab and sitravatinib—two medications that work together to fight cancer—can help prevent hepatocellular carcinoma (liver cancer) from returning after you've had surgery to remove it. You would receive these medications by injection and by mouth. The goal is to see if this combination can improve your chances of staying cancer-free after your surgery.
Even after successful surgery to remove liver cancer, the disease comes back in many patients, which is why doctors are searching for better treatments to give after surgery. This trial is exploring whether this medication combination can reduce the risk of cancer returning and help patients live longer.
You would receive injections of the first medication every 3 weeks, and you would take a pill of the second medication by mouth every day. You would continue this treatment until the cancer returns, you experience unacceptable side effects, or you complete 17 cycles of the injected medication—whichever comes first. Throughout the trial, you would have regular doctor visits and tests to monitor how the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Anhui Provincial Hospital
Collaborators
First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Guangxi Medical University
Enrollment target
~40 participants
Started
July 2022
Primary completion
June 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in March 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lianxin LIU secretary of the party committee
Anhui Provincial Hospital